Swiss pharmaceutical companies plan to cut prices in the US

Illustration photo.

Pfizer recently reached an agreement with US President Donald Trump to postpone tariffs. In return, Pfizer agreed to drastically reduce the prices of some drugs by up to 85% and sell them directly to the American people. Following Pfizer, many other pharmaceutical companies also plan to reduce prices in the US as a way to adapt to the current tariff environment.

Last week, US President Donald Trump announced a 100% tariff on all branded drugs from October 1 unless companies moved production to the US. The move has raised concerns in Switzerland, home to major pharmaceutical companies such as Roche and Novartis.

Pharmaceuticals are a pillar of the Swiss economy and contribute 7-8% of the country's GDP. Experts warn that Switzerland could fall into recession if the US implements this tax plan. To adapt to the current situation, Swiss pharmaceutical companies are planning to sharply reduce the prices of some drugs and sell directly to the American people like Pfizer to avoid tariffs.

"I think the announcement will be made soon and Swiss pharmaceutical companies will follow suit in the coming time. Maybe in a few days or weeks, the deals will be finalized one by one," said Stephan Mumen Thaler, from the Swiss Association for Scientific Technology.

In July, Mr. Trump sent a letter to 17 leading pharmaceutical companies, including Swiss companies Novartis and Roche, asking them to cut prices to match those paid abroad. To reduce drug prices for Americans, foreign drug companies will have to increase production in the United States to cut out middlemen so that consumers receive lower prices.

"Our major members like Novartis, Roche and Lonza... thanks to their investments in the US, have a very high probability of being exempted from these tariffs," said Stephan Mumen Thaler, from the Swiss Association for Scientific Technology.

Meanwhile, small pharmaceutical companies that do not have enough capital to invest heavily in the US will have to look for new markets such as the European Union. However, the number of such companies in Switzerland is not large. Therefore, the pharmaceutical industry here believes that it will be able to adapt well in the context of tariffs that are still unstable, and the first step may be to implement a plan to reduce drug prices in the US.

Source: https://vtv.vn/cac-hang-duoc-thuy-sy-len-ke-hoach-giam-gia-tai-my-100251004095834484.htm